NYSE:NVS Novartis (NVS) Stock Price, News & Analysis $110.30 +0.37 (+0.34%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$109.67▼$110.6650-Day Range$99.39▼$111.7752-Week Range$92.19▼$112.48Volume858,848 shsAverage Volume1.48 million shsMarket Capitalization$225.45 billionP/E Ratio14.89Dividend Yield2.20%Price Target$118.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Novartis alerts: Email Address Novartis MarketRank™ Stock AnalysisAnalyst RatingHold2.14 Rating ScoreUpside/Downside7.1% Upside$118.13 Price TargetShort InterestHealthy0.32% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainabilityN/ANews Sentiment0.84Based on 12 Articles This WeekInsider TradingN/AProj. Earnings Growth11.67%From $7.37 to $8.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.76 out of 5 starsMedical Sector685th out of 936 stocksPharmaceutical Preparations Industry318th out of 436 stocks 1.1 Analyst's Opinion Consensus RatingNovartis has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 2 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageNovartis has only been the subject of 4 research reports in the past 90 days.Read more about Novartis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.32% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Novartis has recently decreased by 0.16%, indicating that investor sentiment is improving. Previous Next 2.5 Dividend Strength Dividend YieldNovartis pays a meaningful dividend of 2.22%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 32.79%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 29.53% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVS. Previous Next 3.2 News and Social Media Coverage News SentimentNovartis has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Novartis this week, compared to 10 articles on an average week.Search InterestOnly 7 people have searched for NVS on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat Follows14 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Novartis is held by insiders.Percentage Held by InstitutionsOnly 13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Novartis are expected to grow by 11.67% in the coming year, from $7.37 to $8.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 14.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 14.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Earnings Growth RatioNovartis has a PEG Ratio of 1.62. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 5.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novartis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Novartis Stock (NYSE:NVS)Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Read More NVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVS Stock News HeadlinesJuly 19, 2024 | marketbeat.comPharma Leader Beats on Earnings, But Shares Fall (NVS)Novartis released its Q2 financial results. It beat expectations on EPS and revenue. However, shares fell, possibly due to bad news on one upcoming drug.July 17, 2024 | marketbeat.comPharmaceutical Stocks - Best Pharmaceutical Stocks to Buy (NVS)Along with biotechnology and biotech companies, the pharma industry is a major part of the overall healthcare market. Pharmaceutical companies include some of the biggest stock gainers and some of the best growth stocks on the market. The pharmaceutical market has many amazing stocks to watch. The pharma industry may also be a good investment for those looking for dividend stocks since so many of the largest pharmaceutical companies pay a dividend to its shareholders. Though the industry has plenty of potential for growth, investors should also be aware that pharma stocks—especially smaller startups—can be risky. Investors buying pharma stocks should make sure to do their research and only invest in pharma stocks as part of a diversified portfolio.July 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 26 at 9:54 PM | reuters.comUS court finds ‘robust’ anti-fraud safeguards in Novartis settlementJuly 24 at 10:52 AM | finance.yahoo.comDren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for CancerJuly 21, 2024 | americanbankingnews.comNovartis' (NVS) Hold Rating Reaffirmed at Deutsche Bank AktiengesellschaftJuly 21, 2024 | americanbankingnews.comNovartis AG (NYSE:NVS) Receives Consensus Rating of "Hold" from BrokeragesJuly 20, 2024 | americanbankingnews.comNovartis (NYSE:NVS) Announces Earnings Results, Beats Expectations By $0.10 EPSJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 20, 2024 | americanbankingnews.comNovartis (NYSE:NVS) Shares Gap Down to $111.80July 20, 2024 | seekingalpha.comNovartis: Another Beat, Another RaiseJuly 20, 2024 | msn.comNVS Earnings: Novartis Beats Q2 Estimates, Raises Profitability OutlookJuly 19, 2024 | seekingalpha.comRoche Holding AG: A More Optimal Investment Vis-A-Vis NVSJuly 19, 2024 | msn.comNovartis lifts profit forecast for second time on Cosentyx, EntrestoJuly 19, 2024 | sg.finance.yahoo.comNovartis raises 2024 profit guidance, stock slipping thoughJuly 19, 2024 | msn.comNovartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key DrugsJuly 19, 2024 | markets.businessinsider.comNovartis Tops on Q2 Earnings, Ups Operating Income ViewJuly 19, 2024 | msn.comPharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill DataSee More Headlines Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/18/2024Today7/26/2024Next Earnings (Estimated)10/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NVS CUSIPN/A CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees76,057Year Founded1996Price Target and Rating Average Stock Price Target$118.13 High Stock Price Target$122.50 Low Stock Price Target$114.00 Potential Upside/Downside+6.8%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$7.41 Trailing P/E Ratio14.92 Forward P/E Ratio15.01 P/E Growth1.62Net Income$14.85 billion Net Margins33.76% Pretax Margin22.75% Return on Equity34.56% Return on Assets14.24% Debt Debt-to-Equity Ratio0.47 Current Ratio0.93 Quick Ratio0.72 Sales & Book Value Annual Sales$45.44 billion Price / Sales4.97 Cash Flow$11.25 per share Price / Cash Flow9.83 Book Value$20.50 per share Price / Book5.39Miscellaneous Outstanding Shares2,044,000,000Free Float2,043,796,000Market Cap$226.05 billion OptionableOptionable Beta0.57 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Vasant Narasimhan M.D. (Age 48)Chief Executive Officer Comp: $8.01MMr. Harry Kirsch (Age 59)Chief Financial Officer Comp: $3.99MMr. Victor Bulto (Age 46)President of US Comp: $3.28MDr. Patrick Horber M.D. (Age 54)President of International Comp: $7.31MDr. Steffen Lang Ph.D. (Age 57)President of Operations Comp: $2.34MPaul PenepentHead of Group Financial Reporting and AccountingMs. Sloan SimpsonGlobal Head of Investor RelationsDr. Klaus Moosmayer Ph.D. (Age 56)Chief Ethics, Risk & Compliance Officer Comp: $1.55MMs. Karen L. Hale (Age 56)Chief Legal Officer Comp: $2.34MDr. Robert Kowalski Pharm.D. (Age 56)Chief People & Organization Officer Comp: $2.1MMore ExecutivesKey CompetitorsEli Lilly and CompanyNYSE:LLYNovo Nordisk A/SNYSE:NVOJohnson & JohnsonNYSE:JNJMerck & Co., Inc.NYSE:MRKAbbVieNYSE:ABBVView All CompetitorsInstitutional OwnershipChecchi Capital Advisers LLCSold 210 shares on 7/26/2024Ownership: 0.001%Simmons BankSold 205 shares on 7/26/2024Ownership: 0.000%Harbour Investments Inc.Bought 273 shares on 7/26/2024Ownership: 0.000%Hall Capital Management Co. Inc.Bought 105 shares on 7/26/2024Ownership: 0.000%Liontrust Investment Partners LLPSold 289 shares on 7/26/2024Ownership: 0.000%View All Institutional Transactions Should I Buy Novartis Stock? NVS Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Novartis AG: Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally, focusing on therapeutic areas such as cardiovascular, renal, metabolic, and immunology. Novartis AG offers prescription medicines for patients and physicians, providing a wide range of healthcare solutions. Cons Investors should be bearish about investing in Novartis AG for these reasons: Novus Energy, Inc. (Novus) is a junior oil and gas company, not related to Novartis AG, which may cause confusion or misinformation for investors. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com. NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $100.97 at the start of the year. Since then, NVS shares have increased by 9.2% and is now trading at $110.30. View the best growth stocks for 2024 here. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) posted its quarterly earnings data on Thursday, July, 18th. The company reported $1.97 EPS for the quarter, topping the consensus estimate of $1.87 by $0.10. The business earned $12.87 billion during the quarter, compared to the consensus estimate of $12.24 billion. Novartis had a net margin of 33.76% and a trailing twelve-month return on equity of 34.56%. What is Vas Narasimhan's approval rating as Novartis' CEO? 938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Novartis have any subsidiaries? The following companies are subsidiaries of Novartis: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and others. Who are Novartis' major shareholders? Novartis' top institutional investors include Bank of New York Mellon Corp (0.09%), Scharf Investments LLC (0.07%), Chevy Chase Trust Holdings LLC (0.05%) and Raymond James & Associates (0.03%). How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS) and Gilead Sciences (GILD). This page (NYSE:NVS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
